Nifty
Sensex
:
:
11408.40
37976.72
54.15 (0.48%)
167.81 (0.44%)

Pharmaceuticals & Drugs

Rating :
65/99

BSE: 532296 | NSE: GLENMARK

650.50
14.85 (2.34%)
26-Mar-2019 | 1:24PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  639.90
  •  651.05
  •  636.30
  •  635.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  345633
  •  2248.34
  •  711.90
  •  493.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,952.95
  • 19.62
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 21,357.64
  • 0.31%
  • 3.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.54%
  • 2.88%
  • 9.33%
  • FII
  • DII
  • Others
  • 2.72%
  • 4.02%
  • 34.51%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.84
  • 8.83
  • 6.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.51
  • 8.17
  • 2.37

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 8.19
  • 2.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.19
  • 30.09
  • 20.76

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.33
  • 5.89
  • 4.62

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.39
  • 15.81
  • 13.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
2,555.05
2,203.66
15.95%
2,581.33
2,256.59
14.39%
2,165.62
2,363.00
-8.35%
2,279.82
2,457.18
-7.22%
Expenses
2,120.37
1,880.97
12.73%
2,141.23
1,868.19
14.62%
1,818.73
1,785.55
1.86%
1,952.98
2,013.34
-3.00%
EBITDA
434.68
322.69
34.71%
440.11
388.40
13.31%
346.88
577.45
-39.93%
326.83
443.84
-26.36%
EBIDTM
17.01%
14.64%
17.05%
17.21%
16.02%
24.44%
14.34%
18.06%
Other Income
-109.02
-23.16
-
139.88
29.73
370.50%
138.22
15.29
803.99%
69.55
-51.29
-
Interest
88.53
70.47
25.63%
85.13
69.84
21.89%
79.01
70.86
11.50%
74.39
69.67
6.77%
Depreciation
83.10
75.38
10.24%
82.45
75.23
9.60%
79.38
77.73
2.12%
73.53
68.90
6.72%
PBT
154.03
153.67
0.23%
579.59
273.05
112.27%
326.70
444.14
-26.44%
248.47
173.03
43.60%
Tax
37.69
48.93
-22.97%
165.59
58.93
180.99%
93.71
110.76
-15.39%
96.84
-10.73
-
PAT
116.34
104.74
11.08%
414.00
214.12
93.35%
232.99
333.38
-30.11%
151.63
183.76
-17.48%
PATM
4.55%
4.75%
16.04%
9.49%
10.76%
14.11%
6.65%
7.48%
EPS
4.12
3.71
11.05%
14.67
7.59
93.28%
8.26
11.81
-30.06%
5.37
6.52
-17.64%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
9,581.82
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
Net Sales Growth
3.25%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
 
Cost Of Goods Sold
3,285.93
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
Gross Profit
6,295.89
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
GP Margin
65.71%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
Total Expenditure
8,033.31
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
Power & Fuel Cost
-
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
% Of Sales
-
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
Employee Cost
-
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
% Of Sales
-
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
Manufacturing Exp.
-
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
% Of Sales
-
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
General & Admin Exp.
-
805.17
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
% Of Sales
-
8.87%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
Selling & Distn. Exp.
-
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
% Of Sales
-
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
Miscellaneous Exp.
-
35.66
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
254.38
% Of Sales
-
0.39%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
EBITDA
1,548.50
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
EBITDA Margin
16.16%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
Other Income
238.63
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
Interest
327.06
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
Depreciation
318.46
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
PBT
1,308.79
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
Tax
393.83
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
Tax Rate
30.09%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
PAT
914.96
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
PAT before Minority Interest
914.90
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
Minority Interest
-0.06
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
PAT Margin
9.55%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
PAT Growth
9.44%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
 
Unadjusted EPS
32.42
28.49
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
Share Capital
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
Total Reserves
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
Non-Current Liabilities
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
Secured Loans
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
Unsecured Loans
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
Current Liabilities
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
Trade Payables
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
Other Current Liabilities
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
Short Term Borrowings
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
Short Term Provisions
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
Total Liabilities
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
Net Block
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
Gross Block
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
Accumulated Depreciation
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
Non Current Assets
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
Capital Work in Progress
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
Non Current Investment
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
Long Term Loans & Adv.
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
Other Non Current Assets
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
Current Assets
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
Sundry Debtors
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
Cash & Bank
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
Other Current Assets
1,391.61
683.39
391.88
31.44
872.81
635.91
593.95
465.11
527.31
422.09
Short Term Loans & Adv.
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
Net Current Assets
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
Total Assets
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
PBT
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
Adjustment
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
Changes in Working Capital
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
Cash after chg. in Working capital
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
Net Fixed Assets
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
Net Investments
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
Others
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
Cash from Financing Activity
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
Net Cash Inflow / Outflow
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
Opening Cash & Equivalents
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
Closing Cash & Equivalent
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
63.79
ROA
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
ROE
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
ROCE
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
Fixed Asset Turnover
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
1.43
Receivable days
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
151.98
Inventory Days
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
88.92
Payable days
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
62.10
Cash Conversion Cycle
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
178.80
Total Debt/Equity
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
1.31
Interest Cover
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32
2.85

News Update:


  • Glenmark’s arm gets USFDA’s final approval for Clindamycin, Benzoyl Peroxide Gel
    15th Mar 2019, 09:56 AM

    The company’s current portfolio consists of 151 products authorized for distribution in the US marketplace

    Read More
  • Glenmark presents new subtype analysis of GBR 830 in Washington
    5th Mar 2019, 11:43 AM

    GBR 830 is an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis

    Read More
  • Glenmark’s arm gets USFDA’s final approval for Telmisartan, Hydrochlorothiazide Tablets
    5th Mar 2019, 10:50 AM

    The company’s current portfolio consists of 150 products authorized for distribution in the US marketplace

    Read More
  • Glenmark to present new analysis of pooled data on Ryaltris
    20th Feb 2019, 09:15 AM

    Ryaltris has been conditionally accepted by the FDA as the brand name

    Read More
  • Glenmark’s arm gets USFDA’s approval for Clobetasol Propionate Foam
    18th Feb 2019, 09:12 AM

    According to IQVIA sales data for the 12 month period ending December 2018, the Olux Foam, 0.05% market achieved annual sales of approximately $50.9 million

    Read More
  • Glenmark reports 11% rise in Q3 consolidated net profit
    15th Feb 2019, 09:59 AM

    Total consolidated income of the company increased by 12.18% at Rs 2446.03 crore for Q3FY19

    Read More
  • Glenmark to spin off its innovation business into new company in US
    15th Feb 2019, 08:57 AM

    The new innovation company will be a wholly-owned subsidiary of Glenmark and will be based in the US

    Read More
  • Glenmark Pharma - Quarterly Results
    14th Feb 2019, 17:13 PM

    Read More
  • Glenmark’s arm gets approval from USFDA for Sevelamer Hydrochloride Tablets
    11th Feb 2019, 09:12 AM

    The company’s current portfolio consists of 149 products authorized for distribution in the US market place and 53 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark’s arm gets tentative approval from USFDA for Fulvestrant Injection
    7th Feb 2019, 09:10 AM

    According to IQVIA sales data for the 12 month period ending December 2018, the FASLODEX Injection

    Read More
  • Glenmark Pharmaceuticals’ arm enters into exclusive license agreement with Grandpharma
    6th Feb 2019, 14:19 PM

    As per the agreement, the company will be responsible to manufacture and supply Ryaltris

    Read More
  • Glenmark receives tentative ANDA approval for Topiramate extended-release capsules
    24th Jan 2019, 09:50 AM

    The company’s current portfolio consists of 148 products authorized for distribution in the US marketplace and 54 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark gets tentative ANDA approval for Abiraterone Acetate Tablets
    23rd Jan 2019, 10:28 AM

    Glenmark’s current portfolio consists of 148 products authorized for distribution in the US marketplace and 54 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharma recalling 96,240 applicators of its product from US
    21st Jan 2019, 10:46 AM

    The USFDA has termed it as a Class-II recall

    Read More
  • Glenmark Pharma’s Suisse arm enters into licensing agreement with Yuhan Corporation
    10th Jan 2019, 09:11 AM

    Under the terms of the agreement, Glenmark will be responsible for manufacturing and supply of the product

    Read More
  • Glenmark aims consolidated revenue growth of 12-15% over next 3-5 years
    9th Jan 2019, 10:09 AM

    This would be mainly on account of strengthening the current business of generics, branded generics, anticipated launch of dermatology etc.

    Read More
  • Glenmark Pharma transfers API business to Glenmark Life Sciences
    2nd Jan 2019, 09:20 AM

    This transfer was completed on December 31, 2018

    Read More
  • Glenmark Pharma forays into branded dermatology segment in US
    19th Dec 2018, 09:08 AM

    The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc.

    Read More
  • Glenmark Pharma presents new data on GBR 1302, HER2xCD3 Bispecific Antibody
    18th Dec 2018, 10:36 AM

    These Phase 1 data will inform dosing regimen optimization of GBR 1302

    Read More
  • Glenmark Pharma receives ANDA approval for Fluocinolone Acetonide Oil
    18th Dec 2018, 09:35 AM

    According to IQVIA sales data for the 12 month period ending October 2018, the DermaOtic Oil, 0.01% (Ear Drops) market achieved annual sales of approximately $18.1 million

    Read More
  • Glenmark Pharma’s arm gets USFDA’s approval for Hydrocortisone Valerate Ointment
    17th Dec 2018, 09:12 AM

    This is Glenmark’s first granted CGT product approved by the USFDA

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.